1								
1	XAVIER BECERRA							
2	Attorney General of California MARC D. GREENBAUM							
3	Supervising Deputy Attorney General MORGAN MALEK							
4	Deputy Attorney General State Bar No. 223382							
5	300 So. Spring Street, Suite 1702							
	Los Angeles, CA 90013 Telephone: (213) 897-2643							
6	Facsimile: (213) 897-2804 Attorneys for Complainant							
7								
8	BEFOR BOARD OF F							
9	DEPARTMENT OF CO STATE OF C	ONSUMER AFFAIRS						
10		1						
11	In the Matter of the Accusation Against:	Case No. 5321						
12	THE DRUGGIST, INC.,	OAH No. 2017120806						
13	JOEL ABERGEL, OWNER 27867 Smyth Drive							
14	Valencia, CA 91355	THIRD AMENDED ACCUSATION						
15	Pharmacy Permit No. PHY 50146,							
16	and							
17	JOEL ABERGEL AKA JOELLE							
18	ABERGEL 23905 Lakeside Road							
19	Santa Clarita, CA 91355							
20	Pharmacist License No. RPH 41192							
21	Respondents.							
22	Complement alleges							
23	Complainant alleges:							
24	<u>PARTIES</u>							
25	1. Anne Sodergren ("Complainant") brings this Accusation solely in her official							
26	capacity as the Interim Executive Officer of the Board of Pharmacy, Department of Consumer							
27	Affairs.							
28								
		1						

- 2. On or about June 10, 2010, the Board of Pharmacy issued Pharmacy Permit Number PHY 50146 to The Druggist Inc. to do business as The Druggist Inc. ("Respondent Pharmacy"). Joel Abergel has been the owner, President, and Pharmacist-in-Charge of Respondent Pharmacy since June 10, 2019. The Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein and will expire on April 30, 2019, unless renewed.
- 3. On or about September 26, 1987, the Board of Pharmacy issued Pharmacist License Number RPH 41192 to Joel Abergel aka Joelle Abergel ("Respondent Abergel"). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on April 30, 2019, unless renewed.

#### **JURISDICTION**

- 4. This Accusation is brought before the Board of Pharmacy ("Board"), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.
  - 5. **Section 4300.1** of the Code states:

"The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license."

- 6. **Section 4300** of the Code states, in pertinent part:
- "(a) Every license issued may be suspended or revoked.
- "(b) The board shall discipline the holder of any license issued by the board, whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:
  - "(1) Suspending judgment.
  - "(2) Placing him or her upon probation.
  - "(3) Suspending his or her right to practice for a period not exceeding one year.
  - "(4) Revoking his or her license.

	1
	2
	3
	4
	5
	6
	7
	8
	9
1	0
1	1
1	2
1	3
1	4
1	5
1	6
1	7
1	8
1	9
2	0
2	1
2	2
2	3
2	4
2	5
2	6
2	7

"(5) Taking any other action in relation to disciplining him or her as the board in its discretion may deem proper.

. . . .

"(e) The proceedings under this article shall be conducted in accordance with Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code, and the board shall have all the powers granted therein. The action shall be final, except that the propriety of the action is subject to review by the superior court pursuant to Section 1094.5 of the Code of Civil Procedure."

#### STATUTES AND REGULATIONS

- 7. **Section 4081**, subdivision (a) of the Code states:
- "(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall be kept by every manufacturer, wholesaler, third-party logistics provider, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous drugs or dangerous devices."
  - 8. **Section 4301** of the Code states, in pertinent part:

"The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

. . . .

"(j) The violation of any of the statutes of this state, or any other state, or of the United States regulating controlled substances and dangerous drugs.

. . . .

- "(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency."
  - 9. **Section 4307**, subdivision (a), of the Code states, in pertinent part:
- (a) Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of any partnership, corporation, trust, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control had knowledge of or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, partner, or in any other position with management or control of a licensee as follows:
- (1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.
- (2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.
- (b) "Manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of a license" as used in this section and Section 4308, may refer to a pharmacist or to any other person who serves in such capacity in or for a licensee.
- (c) The provisions of subdivision (a) may be alleged in any pleading filed pursuant to Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code. However, no order may be issued in that case except as to a person who is named in the caption, as to whom the pleading alleges the applicability of this section, and where the person has been given notice of the proceeding as required by Chapter 5 (commencing with Section 11500) of Part

1 of Division 3 of the Government Code. The authority to proceed as provided by this subdivision shall be in addition to the board's authority to proceed under Section 4339 or any other provision of law.

10. **Section 4332**, subdivision (a), of the Code states, in pertinent part:

"Any person who fails, neglects, or refuses to maintain the records required by Section 4081 or who, when called upon by an authorized officer of a member of the board, fails, neglects, or refuses to produce or provide the records within a reasonable time, or who willfully produces or furnishes records that are false, is guilty of a misdemeanor.

#### 11. Health and Safety Code section 11153 states, in pertinent part:

"(a) A prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. Except as authorized by this division, the following are not legal prescriptions: (1) an order purporting to be a prescription which is issued not in the usual course of professional treatment or in legitimate and authorized research; or (2) an order for an addict or habitual user of controlled substances, which is issued not in the course of professional treatment or as part of an authorized narcotic treatment program, for the purpose of providing the user with controlled substances, sufficient to keep him or her comfortable by maintaining customary use."

- 12. California Code of Regulations, title 16, section 1715.6 states, "[t]he owner shall report to the Board within thirty (30) days of discovery of any loss of the controlled substances, including their amounts and strengths."
  - 13. California Code of Regulations, title 16, section 1718 states:

"'Current Inventory' as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

"The controlled substances inventories required by Title 21, CFR, Section 1304 shall be available for inspection upon request for at least 3 years after the date of the inventory."

- 14. California Code of Regulations, title 16, section 1761 states:
- "(a) No pharmacist shall compound or dispense any prescription which contains any significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any such prescription, the pharmacist shall contact the prescriber to obtain the information needed to validate the prescription.
- "(b) Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose."
- 15. Code of Federal Regulations, title 21, section 1304.04, subdivision (h), states in pertinent part:
- "(h) Each registered pharmacy shall maintain the inventories and records of controlled substances as follows:
- "(1) Inventories and records of all controlled substances listed in Schedule I and II shall be maintained separately from all other records of the pharmacy.
- "(2) Paper prescriptions for Schedule II controlled substances shall be maintained at the registered location in a separate prescription file.
- "(3) Inventories and records of Schedules III, IV, and V controlled substances shall be maintained either separately from all other records of the pharmacy or in such form that the information required is readily retrievable from ordinary business records of the pharmacy."

# **CONTROLLED SUBSTANCES/DANGEROUS DRUGS**

- 16. **Hydromorphone, the generic name for Dilaudid**, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(J) and is a dangerous drug pursuant to Code section 4022.
- 17. **Hydrocodone and acetaminophen ("hydrocodone/apap"), the generic name for Norco and Lortab**, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (e)(4) and is a dangerous drug pursuant to Code section 4022. As of October 6, 2014, hydrocodone/apap became a Schedule II controlled substance pursuant to United States Code, title 21, section 812.

- 18. **Oxycodone, the generic name for Oxycontin**, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M) and is a dangerous drug pursuant to Code section 4022.
- 19. Oxycodone and acetaminophen, the generic name for Percocet and Endocet, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M), and is a dangerous drug pursuant to Code section 4022.

#### **COST RECOVERY**

20. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case, with failure of the licentiate to comply subjecting the license to not being renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be included in a stipulated settlement.

## **BOARD'S INSPECTION OF DECEMBER 2012**

- 21. On 12/19/2012, Inspector A.N. and Inspector R.V. traveled to Respondent Pharmacy. Respondent Abergel, and Pharmacy Technicians R.E. and J.R. were present. The inspectors explained to Respondent Abergel that they were there to perform a routine inspection and request and pick up some documents.
- 22. On or about June 5, 2012, the Board of Pharmacy became aware of an article that an anonymous tip led deputies to arrest several members of a suspected local drug ring. The main suspect, M.L., was arrested on or about January 31, 2012, with nearly 700 oxycodone pills in his possession, estimated to have a street resale value of \$10,000, in Respondent's Pharmacy's parking lot. Subsequent investigation revealed that the oxycodones were purchased from Respondent Pharmacy. M.L. was charged for several felonies and ultimately he was convicted on April 2, 2012, for felony charge of possession for sale of controlled substances and felony charge of procuring or attempting to procure the administration of or prescription for controlled substances, (1) by fraud, deceit, misrepresentation, or subterfuge; or (2) by the concealment of a material fact. M.L. was ordered to serve two (2) years in county jail." On or about April 5, 2012,

Captain of Santa Clarita Valley Station Sheriff's Department sent a letter to Respondent PIC notifying him that several individuals entered Respondent Pharmacy to purchase oxycodone with a prescription, and deliver the oxycodone pills to [M.L.] sitting in his car parked in front of Respondent Pharmacy. The Captain further explained that fraudulent prescriptions were being filled at Respondent Pharmacy for individuals who do not reside within the City of Santa Clarita. He asked Respondent PIC to institute a policy preventing the criminal element from traveling to the City of Santa Clarita by refusing to fill and/or call to verify prescriptions for narcotics if the prescribing physician or patient did not reside in the City of Santa Clarita.

- 23. Inspector R.V. proceeded to a perform a physical inspection of the pharmacy and reviewed the prescription files while Inspector A.N. inspected the compounding area. Inspector R.V. examined the Schedule II prescription files and noticed a large number of the prescriptions were from patients out of the area, were mainly from 4 5 doctors out of the area and were filled in sequence, meaning filled one right after the other. He questioned Respondent Abergel about these prescriptions and asked if he saw each patient in the pharmacy. Respondent Abergel informed Inspector R.V. some of the patients he never saw nor provided consultation in person for new prescriptions dispensed. The prescriptions were given to him by "drivers". Respondent Abergel did not have any copies of any type of identification for the drivers. The prescriptions were mostly for Dilaudid 4mg, Oxycodone 30mg and Percocet 10/325 (Endocet). Inspector R.V. secured 993 of these prescriptions. Inspector R.V. asked Respondent Abergel do a "Stock on Hand" inventory on brand and generic forms of Dilaudid 4mg, Oxycodone 30mg and Endocet 10/325. He requested the last DEA Biennial Inventory.
- 24. Inspector R.V. asked Respondent Abergel if Respondent Druggist had any break-ins or losses. Respondent Abergel provided a "Report of Theft or Loss of Controlled Substances" and the card of the investigator from the local sheriff's department. However, there were no loss of drugs Inspector R.V. was going to audit on the loss report. Respondent Abergel further informed Inspector R.V. that he did not report the loss to the Board.

- 25. Inspector A.N. obtained prescription labels that were not in compliance with pharmacy law and in addition a corrected form that was compliant. Inspector R.V. filled out an Inspection Report, noted the discussed items and requested the following:
  - All invoices from all wholesalers for brand and generic forms Dilaudid 4mg, oxycontin 30mg, and percocet10/325 from 7/8/2010 to 12/18/2012 to be sent to Inspector R.V..
  - Drug utilization report for brand and generic forms of Dilaudid 4mg, Oxycontin 30mg and Percocet 10/325 from 7/8/2010 - 12/18/2012 to include name and addresses of patients and doctors, RX no., date, drug, quantity, days supply and method of payment.
  - Control substance log (daily logs) for all control substances from 7/8/2010 to
     12/18/2012 to include names and addresses of patients and doctors, rx no, rx date,
     drug, quantity, days' supply and method of payment to be in excel format.
  - All DUR and logs to be on separate cd's or flash drives (2 copies of each) to be sent, and all invoices from all wholesalers for brand and generic forms for Dilaudid 4mg, to Inspector R.V., PO Box 594, San Clemente, CA 92674 by 12/22/2012.
- 26. Inspector R.V. issued Official Receipt # 200191 for the secured documents, and the inspectors left.
- 27. On March 28, 2013, Inspector R.V. sent out letters to 5 patients of Respondent Druggist requesting an interview. All 5 letters were returned as undeliverable (Not included in report, but held in evidence).
- 28. On or about January 4, 2013, Inspector R.V. received the requested documents from The Druggist which consisted of:
  - Cover letter from Respondent Abergel and his wife (Exhibit 8, 4 pages). Respondent Abergel stated the doctor's office asked him to deliver the prescriptions to their office after a driver delivered them to the pharmacy. Later it was changed to a driver delivering

- the prescription documents and then picking up the filled prescriptions the next day.

  Respondent Abergel stated his wife called the DEA and the state Board.
- Mrs. Abergel stated she and her husband met with the Pain Management Physicians in
  Van Nuys and they were asked to deliver prescriptions to their office. The wife then called
  the DEA and the state board and was informed nothing prohibited delivering to a doctor's
  office.
- Last page of the document was the corrections they made as a result of the inspection.
- I received the flash drives with DURs for Dilaudid 4mg, oxycodone 30 and Endocet 10/325 (not included in report, but held in evidence).
- The Druggist also provided invoices from H.D. Smith and Valley Wholesale for the 3 drugs.
- 29. Inspector R.V. printed out the DUR's from the flash drive provided by Respondent Druggist. That document showed Respondent Druggist dispensed 16,640 tablets of Dilaudid 4mg and 2,575 tablets of generic Hydromorphone 4mg for a total of 19,215 tablets; 249,152 tablets of Oxycodone 30mg and 53,516 tablets of Endocet 10/325 from 7/8/2010 to 12/18/2012.
- 30. Inspector R.V. entered the invoices provided by Respondent Druggist from H.D. Smith and Valley Wholesale for the 3 drugs onto a spread sheet which showed Respondent Druggist purchased 18,000 tablets of Dilaudid 4mg, 224,500 tablets of Oxycodone 30mg and 50,400 tablets of Endocet 10/325 from 7/8/2010 to 12/18/2012.
- 31. On June 30, 2014 and July 24, 2014, Inspector R.V. forwarded letters to H.D. Smith and Valley Wholesale requesting records of sales to Respondent Druggist for Dilaudid 4mg brand and generic, Oxycodone 30mg and Endocet 10/325 from 7/8/2010 12/18/2012. Her further sent another letter to H.D. Smith on July 29, 2014 requesting additional information.
- 32. On or about July 20, 2014, Inspector R.V. received the requested records from Valley Wholesale, in Excel format, which showed Respondent Druggist purchased 15, 100 tablets of Dilaudid 4mg, 44,500 tablets of Endocet 10/325, 2,400 tablets of Hydromorphone 4mg, 54,500 tablets of Oxycodone 30mg (bottles of 100), 90,500 tablets of Oxycodone 30mg (bottles of 500),

an additional 55,700 tablets of Oxycodone 30mg (Mallinckrodt) and 400 Oxycodone Acetaminophen 10/325.

- 33. On or about July 29, 2014, Inspector R.V. received the reply from H.D. Smith in Excel format which showed Respondent Druggist purchased 19,300 tablets of Dilaudid 4mg, 248,800 tablets of Oxycodone 30mg and 54,100 tablets of Endocet 10/325.
- 34. When compared to the invoices provided by Respondent Druggist, it revealed that Respondent Druggist did not provide invoices for 800 tablets of Dilaudid 4mg, 24,300 tablets of oxycodone 30mg and 3,700 tablets of Endocet 10/325.
- 35. Using the DEA inventory of 7/8/2010 as the initial amount, the invoices provided by the wholesalers as the amount ordered, the DUR's provided by Respondent Druggist as the amount dispensed and the Stock on Hand inventory as the ending inventory, Inspector R.V. performed a "Selected Drug Audit Summary" which Respondent Druggist did not account for 74 Dilaudid 4mg, 164 Oxycodone 30mg and 584 Endocet 10/325.
- 36. Examination of the 993 prescription secured from Respondent Druggist showed the majority were written by:
  - Dr. C. A., located in Inglewood
  - Dr. R. C., located in Studio City
  - Dr. B. O., located at 7035 Reseda Blvd., Reseda
  - Dr. J. G., located at 7035 Reseda Blvd., Reseda
  - Dr. R. L., located at 7035 Reseda Blvd., Reseda
  - Dr. R. S., located at 7035 Reseda Blvd., Reseda
  - Dr. H. S., located in Los Angeles
  - 37. Inspector R.V. included samples of the secured prescriptions from The Druggist:
    - On April 29, 2011, there were 12 prescriptions from Drs. B.O. and Dr. J.G. for Endocet 10/325, Oxycodone 30mg and Dilaudid 4mg. Patients came from Los Angeles, Canoga Park, Burbank, N. Hollywood, and Panorama City. The prescription numbers were in sequence showing the patients or prescriptions came in the same time.

- On May 6, 2011, there were 14 prescriptions from Drs. J.G., R.L., and B.O. for
  Oxycodone 30mg, Endocet 10/325, and Dilaudid 4mg. Patients were from Los
  Angeles, Beverly Hills, and North Hollywood. Prescriptions were in sequence.
- On June 6, 2011, there were 20 prescriptions from Drs. J.G., R.L., B.O. for
   Oxycodone 30mg and Endocet 10/325. Patients were from S. Los Angeles, Rialto,
   Hacienda Heights, Gardena, California City, Venice and Moreno Valley.
   Prescription numbers were in sequence.
- On July 21, 2011, there were 17 prescriptions from Drs. B.O., J.G., R.L., and R.S. (all same office address) for Endocet 10/325, Lortabs, Hydrocodone/apap 10/325,
   Oxycodone 30mg, Norco, and Dilaudid 4mg. Patients came from S. Los Angeles,
   N. Hollywood, Sylmar, S. Pasadena, Mission Viejo, Palm Springs and Norwalk.
   Prescriptions were in sequence.
- On August 16, 2011, there were 16 prescriptions from Drs. J.G., R.L., R.S., and B.O. for oxycodone 30mg, Endocet 10/325 and Dilaudid 4mg. Patients were from S. Los Angeles, Inglewood, Santa Monica, Pomona, Compton, Manhattan Beach, Paramount, and Glendale. Prescriptions were in sequence.
- On January 30, 3012, there were 12 prescriptions from Drs. C.A. and H.S. for
   Oxycodone 30mg. Each doctor had the same dosage for his patient. The patients
   came from Compton, S. Los Angeles, Northridge, Long Beach, Sylmar, Mission
   Hills and Inglewood. The prescription numbers were in sequence.
- On February 2, 2012, there were 11 prescriptions from Dr. C.A. for Oxycodone 30mg. All of the patients had the same dosage.
- On February 9, 2012, there were 10 prescriptions from Dr. R.C. for Oxycodone
   30mg. Patients were from Los Angeles, Inglewood and Sylmar. The prescription numbers were in sequence.
- 38. In summary, Respondent Druggist filled these prescriptions when there too many red flags for the pharmacist not to notice that these prescriptions were not for a legitimate medical purpose:

- Doctors were out of area and patients were as far as Palm Springs.
- Patients were given the same medication and the same dosage.
- Drivers provided no identification and no proof they were working for the doctor.
- The Druggist did not obtain CURES reports for these patients to determine if they were doctor shopping, obtaining prescriptions from multiple pharmacies.
- 39. Inspector R.V. obtained some patient profiles (Respondent Druggist DUR's) and Patient Activity Reports (PAR) from CURES on patients of Respondent Druggist which showed:
  - Patient profile for R.A located in West Hollywood showed from 5/1/2012 to
     7/242012 obtained prescriptions for Oxycodone 30mg from 3 doctors as far away as
     Corona. The PAR showed R.A. obtained prescriptions for Oxycodone from 8 doctors and 7 pharmacies within a year.
  - Respondent Druggist's own patient profile for R.A. #2 showed in 4 months he had obtained Oxycodone 30mg from 4 doctors from Woodland Hills to Corona.
  - PAR for A.C. showed he obtained Oxycodone 30mg from 3 pharmacies and 4 doctors within 11 months.
  - PAR for D.G. living in Long Beach showed he obtained Oxycodone and other controlled substances from 7 pharmacies (from Long Beach, Ontario to Valencia) and from 7 doctors.
  - PAR for S.H. living in Los Angeles showed the patient obtained Oxycodone 30mg from 9 pharmacies from Los Angeles to Desert Hot Springs and 9 doctors from Los Angeles to Corona, while obtaining Oxycodone 30mg from Respondent Druggist.
  - Respondent Druggist's own patient profile for H.L. living in Lancaster, had Rx # 60232, dated 12/1/2011 for 120 Oxycodone 30mg (30 days' supply) by Dr. C. and Rx # 60925, dated 12/20/2011 for 180 oxycodone (30 DS) by Dr. A., 11 days early. The PAR for H.L. shows the patient went to 9 pharmacies from Los Angeles to Lancaster and 7 doctors from Los Angeles to Corona while obtaining prescriptions from Respondent Druggist.

- The PAR for A.J. living in Riverside shows the patient went to 5 pharmacies from Long Beach, Gardena to Valencia and to 4 doctors from Long Beach, Panorama City to Los Angeles while obtaining controlled substances from Respondent Druggist.
- The PAR for B.M. (Exhibit 32, 1 page) shows the patient had Rx # 541124, dated 1/6/2012 for 180 oxycodone 30mg (30ds) at another pharmacy by Dr. A.. The Druggist filled Rx # 62258, dated 1/28/2012 for 180 Oxycodone 30mg by Dr. M.S., 8 days early. The patient had Rx # 54424, dated 3/2/2012 for 180 Oxycodone 30mg (30 DS) at another pharmacy by Dr. A. Respondent Druggist filled Rx # 64202, dated 3/12/2012 for 150 Oxycodone 30mg by Dr. S., 20 days early.
- The Par for N.E. shows the patient went to 4 pharmacies and 6 doctors while obtaining prescriptions for controlled substances while obtaining prescriptions from Respondent Druggist.
- The PAR for J.O., living in N. Hollywood, had Rx # 348972, written by Dr. G. dated 1/7/2011 for 90 Oxycodone 30mg (30DS) dispensed at another pharmacy.

  Respondent Druggist filled Rx # 46862, dated 1/10/2011, written by Dr. B. for 100 Oxycodone 30 mg (20DS), 23 days early. J.O. had Rx # 353146, dated 2/11/2011, written by Dr. G. for 90 Oxycodone 30mg (30DS). Respondent Druggist filled Rx 48699, dated 2/21/2011, written by Dr. B. for 100 Oxycodone 30mg, 20 days early. J.O. had Rx # 49276, dated 3/7/2011, written by Dr. B. for 100 Oxycodone 30mg (20DS) dispensed at Respondent Druggist. J.O had Rx # 356523, dated 3/11/2011, written by Dr. G. for 90 Oxycodone 30mg (30DS) dispensed at another pharmacy. J.O. now has 50 day supply of Oxycodone 30mg at home. Respondent Druggist filled Rx # 49789, dated 3/21/2011, written by Dr. B. for 100 Oxycodone 30mg (20DS), 40 days early. Further, Respondent Druggist filled Rx # 50328, dated 4/4/2011, written by Dr. Dr. B. for 100 Oxycodone 30mg, over 7 days early. J.O. had Rx # 274305, dated 1/31/2012, written by Dr. E. for 150 Oxycodone 30mg (25DS). Respondent Druggist filled Rx # 62922, dated 2/13/2012, written by Dr. G.

28

- for 60 oxycodone 30mg. 12 days early. J.O went to 9 pharmacies from Valencia, Lancaster to Panorama City and 7 doctors while obtaining prescriptions for controlled substances from Respondent Druggist.
- 40. Had Respondent Druggist obtained PAR's and reviewed their own patient profiles for these patients they would have noticed the multiple pharmacies, multiple doctors and early refills.
- 41. On August 14, 2014, Inspector R.V. issued a Written Notice for violation of California Code of Regulation sections 1761(a), 1715.6, 1718; Business and Professions section 4081(a) and Health and Safety Code section 11153(a).

#### FIRST CAUSE FOR DISCIPLINE

# (Filling of Erroneous or Uncertain Prescriptions and Failure to Assume Co-Responsibility in Legitimacy of a Prescription)

42. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under California Code of Regulations section 1761, subd. (a) in conjunction with Health and Safety Code section 11153, subd (a), and Bus. Prof. C. §§4113, 4156, 4301, 4301(d), 4301 (j), 4301(o), 4302, 4035 and 4306.5, in conjunction with Health & Safety C. §11153, subdivision (a), and pursuant to Vermont & 110th Medical Arts v. Board of Pharmacy (1981) 125 Cal.App.3d 19 (hereinafter referred as Vermont), pursuant to Sternberg v. Board of Pharmacy (2015) 239 Cal. App. 4th 1159 (hereinafter referred as Sternberg), and pursuant to the Board of Pharmacy's Precedential Decision No. 2013-01 (Board of Pharmacy v. Pacifica Pharmacy Corporation, et al., (2012) Case No. 3802, OAH No. 2011010644) (hereinafter referred as Pacifica), Arenstein v. Cal. State Bd. of Pharmacy (1968) 265 Cal. App. 2d 179, 192, on the grounds of unprofessional conduct because Respondents failed to exercise or implement their best professional judgment or their corresponding responsibility to ensure that controlled substances are dispensed for a legitimate medical purpose, in that Respondents compounded or dispensed prescriptions which contain significant error, omission, irregularity, uncertainty, ambiguity or alteration. Respondents failed to contact the prescriber to obtain the information needed to validate the prescription. Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said

prescription was not issued for a legitimate medical purpose and in filling these prescriptions. Respondent Druggist filled prescriptions for habitual doctor shoppers and erroneous/uncertain prescriptions as set forth in paragraphs 56 and 57. J.O went to 9 pharmacies from Valencia, Lancaster to Panorama City and 7 doctors while obtaining prescriptions for controlled substances from The Druggist. Filling prescriptions for controlled substances for patients from all areas of Southern California coming in at the same time and also from doctors out of the area. These prescriptions for controlled substance were filled and provided to un-identified, unauthorized drivers without confirming with the patient.

43. Complainant refers to and by this reference incorporates the allegations set forth above in paragraphs 21-41, inclusive, as though set forth fully.

# **SECOND CAUSE FOR DISCIPLINE**

## (Failure to Keep Complete Accountability)

- 44. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under California Code of Regulations section 1718, in conjunction with Code sections 4081 and 4332, and California Federal Regulations, Title 21, section 1304, and Bus. Prof. C. §4113, and Stenberg, in that based on records from 7/8/2010 12/18/2012, Respondents failed to account for 74 tablets of Dilaudid 4mg, 164 tablets of Oxycodone 30mg and 584 tablets of Endocet 10/325.
- 45. Complainant refers to and by this reference incorporates the allegations set forth above in paragraphs 21-41, inclusive, as though set forth fully.

#### THIRD CAUSE FOR DISCIPLINE

#### (Failure to Notify Board of Loss of Controlled Substances)

- 46. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action Under California Code of Regulations, Title 16, section 1715.6, and Bus. Prof. C. §4113, and Stenberg, in that Respondents failed to report the loss of 400 Hydrocodone/apap 5/500, 200 Hydrocodone/apap 7.5/750, 480 Hydrocodone/apap 10/650, 180 Hydrocodone/apap 10/325 and 260 Hydrocodone/apap 10/325 on 9/3/2012.
  - 47. Complainant refers to and by this reference incorporates the allegations set forth

3

# **OTHER MATTERS**

- 4 5
- 6 7

8

- 9 10 11
- 12 13
- 14

15

16 17

18

19

20

21

22 23

24 25

26

27

48. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 50146 issued to The Druggist Inc., The Druggist Inc. shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if it is revoked.

49. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 50146 issued to The Druggist Inc. while Joel Abergel has been an officer and owner and had knowledge of or knowingly participated in any conduct for which the licensee was disciplined, Joel Abergel shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if it is revoked.

# DISCIPLINE CONSIDERATIONS

50. To determine the degree of discipline, if any, to be imposed on Respondent Abergel, Complainant alleges that on or about October 31, 2007, the Board of Pharmacy issued a Citation to Respondent Abergel in Case No. CI 2007 34523 in the amount of \$4,000.00 for violating California Code of Regulations, title 16, section 1714, subdivision (d) [theft policy]. That Citation is now final and is incorporated by reference as if fully set forth.

#### <u>PRAYER</u>

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- Revoking or suspending Pharmacy Permit Number PHY 50146 issued to The Druggist, Inc.;
- 2. Revoking or suspending Pharmacist License Number RPH 41192 issued to Joel Abergel aka Joelle Abergel;

1	XAVIER BECERRA					
2	Attorney General of California MARC D. GREENBAUM					
3	Supervising Deputy Attorney General MORGAN MALEK					
4	Deputy Attorney General State Bar No. 223382					
5	300 So. Spring Street, Suite 1702 Los Angeles, CA 90013					
6	Telephone: (213) 897-2643 Facsimile: (213) 897-2804					
7	Attorneys for Complainant					
8	BEFOR	E THE				
9	BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS					
10	STATE OF CA					
11	In the Motter of the Assuration Assingte	Case No. 5321				
12	In the Matter of the Accusation Against:	OAH No. 2017120806				
13	THE DRUGGIST, INC., JOEL ABERGEL, OWNER	OAH NO. 2017120800				
ľ	27867 Smyth Drive Valencia, CA 91355					
14		SECOND AMENDED ACCUSATION				
15	Pharmacy Permit No. PHY 50146,	. •				
16	and					
17	JOEL ABERGEL AKA JOELLE					
18	ABERGEL 23905 Lakeside Road					
19	Santa Clarita, CA 91355					
20	Pharmacist License No. RPH 41192	·				
21	Respondents.					
22	Complainant alleges:					
23	PARTIES					
24						
25	1. Virginia Herold ("Complainant") brings this Accusation solely in her official capacity					
26	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.					
27	2. On or about June 10, 2010, the Board of Pharmacy issued Pharmacy Permit Number					
28	PHY 50146 to The Druggist Inc. to do business as	The Druggist Inc. ("Respondent Pharmacy").				
ļ!		•				

Joel Abergel has been the owner, President, and Pharmacist-in-Charge of Respondent Pharmacy since June 10, 2019. The Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein and will expire on June 1, 2016, unless renewed.

3. On or about September 26, 1987, the Board of Pharmacy issued Pharmacist License Number RPH 41192 to Joel Abergel aka Joelle Abergel ("Respondent Abergel"). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on April 30, 2019, unless renewed.

#### **JURISDICTION**

- 4. This Accusation is brought before the Board of Pharmacy ("Board"), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.
  - 5. **Section 4300.1** of the Code states:

"The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license."

- 6. Section 4300 of the Code states, in pertinent part:
- "(a) Every license issued may be suspended or revoked.
- "(b) The board shall discipline the holder of any license issued by the board, whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:
  - "(1) Suspending judgment.
  - "(2) Placing him or her upon probation.
  - "(3) Suspending his or her right to practice for a period not exceeding one year.
  - "(4) Revoking his or her license.
- "(5) Taking any other action in relation to disciplining him or her as the board in its discretion may deem proper.

. . . .

"(e) The proceedings under this article shall be conducted in accordance with Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code, and the board shall have all the powers granted therein. The action shall be final, except that the propriety of the action is subject to review by the superior court pursuant to Section 1094.5 of the Code of Civil Procedure."

# STATUTES AND REGULATIONS

7. **Section 4081**, subdivision (a) of the Code states:

"(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall be kept by every manufacturer, wholesaler, third-party logistics provider, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous drugs or dangerous devices."

8. Section 4301 of the Code states, in pertinent part:

"The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

• • • •

"(j) The violation of any of the statutes of this state, or any other state, or of the United States regulating controlled substances and dangerous drugs.

. . .

"(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable

federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency."

- 9. Section 4307, subdivision (a), of the Code states, in pertinent part:
- (a) Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of any partnership, corporation, trust, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control had knowledge of or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, partner, or in any other position with management or control of a licensee as follows:
- (1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.
- (2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.
- (b) "Manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of a license" as used in this section and Section 4308, may refer to a pharmacist or to any other person who serves in such capacity in or for a licensee.
- (c) The provisions of subdivision (a) may be alleged in any pleading filed pursuant to Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code. However, no order may be issued in that case except as to a person who is named in the caption, as to whom the pleading alleges the applicability of this section, and where the person has been given notice of the proceeding as required by Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code. The authority to proceed as provided by this subdivision

shall be in addition to the board's authority to proceed under Section 4339 or any other provision of law.

10. Section 4332, subdivision (a), of the Code states, in pertinent part:

"Any person who fails, neglects, or refuses to maintain the records required by Section 4081 or who, when called upon by an authorized officer of a member of the board, fails, neglects, or refuses to produce or provide the records within a reasonable time, or who willfully produces or furnishes records that are false, is guilty of a misdemeanor.

#### 11. Health and Safety Code section 11153 states, in pertinent part:

- "(a) A prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. Except as authorized by this division, the following are not legal prescriptions: (1) an order purporting to be a prescription which is issued not in the usual course of professional treatment or in legitimate and authorized research; or (2) an order for an addict or habitual user of controlled substances, which is issued not in the course of professional treatment or as part of an authorized narcotic treatment program, for the purpose of providing the user with controlled substances, sufficient to keep him or her comfortable by maintaining customary use."
- 12. California Code of Regulations, title 16, section 1715.6 states, "[t]he owner shall report to the Board within thirty (30) days of discovery of any loss of the controlled substances, including their amounts and strengths."
  - 13. California Code of Regulations, title 16, section 1718 states:

"'Current Inventory' as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

"The controlled substances inventories required by Title 21, CFR, Section 1304 shall be available for inspection upon request for at least 3 years after the date of the inventory."

14. California Code of Regulations, title 16, section 1761 states:

"(a) No pharmacist shall compound or dispense any prescription which contains any
significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any
such prescription, the pharmacist shall contact the prescriber to obtain the information needed to
validate the prescription.

- "(b) Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose."
- 15. Code of Federal Regulations, title 21, section 1304.04, subdivision (h), states in pertinent part:
- "(h) Each registered pharmacy shall maintain the inventories and records of controlled substances as follows:
- "(1) Inventories and records of all controlled substances listed in Schedule I and II shall be maintained separately from all other records of the pharmacy.
- "(2) Paper prescriptions for Schedule II controlled substances shall be maintained at the registered location in a separate prescription file.
- "(3) Inventories and records of Schedules III, IV, and V controlled substances shall be maintained either separately from all other records of the pharmacy or in such form that the information required is readily retrievable from ordinary business records of the pharmacy."

# CONTROLLED SUBSTANCES/DANGEROUS DRUGS

- 16. **Hydromorphone, the generic name for Dilaudid**, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(J) and is a dangerous drug pursuant to Code section 4022.
- 17. Hydrocodone and acetaminophen ("hydrocodone/apap"), the generic name for Norco and Lortab, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (e)(4) and is a dangerous drug pursuant to Code section 4022. As of October 6, 2014, hydrocodone/apap became a Schedule II controlled substance pursuant to United States Code, title 21, section 812.

18. Oxycodone, the generic name for Oxycontin, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M) and is a dangerous drug pursuant to Code section 4022.

19. Oxycodone and acetaminophen, the generic name for Percocet and Endocet, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M), and is a dangerous drug pursuant to Code section 4022.

#### **COST RECOVERY**

20. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case, with failure of the licentiate to comply subjecting the license to not being renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be included in a stipulated settlement.

## **BOARD'S INSPECTION OF DECEMBER 2012**

- 21. On 12/19/2012, Inspector A.N. and Inspector R.V. traveled to Respondent Pharmacy. Respondent Abergel, and Pharmacy Technicians R.E. and J.R. were present. The inspectors explained to Respondent Abergel that they were there to perform a routine inspection and request and pick up some documents.
- 22. Inspector R.V. proceeded to a perform a physical inspection of the pharmacy and reviewed the prescription files while Inspector A.N. inspected the compounding area. Inspector R.V. examined the Schedule II prescription files and noticed a large number of the prescriptions were from patients out of the area, were mainly from 4 5 doctors out of the area and were filled in sequence, meaning filled one right after the other. He questioned Respondent Abergel about these prescriptions and asked if he saw each patient in the pharmacy. Respondent Abergel informed Inspector R.V. some of the patients he never saw nor provided consultation in person for new prescriptions dispensed. The prescriptions were given to him by "drivers". Respondent Abergel did not have any copies of any type of identification for the drivers. The prescriptions were mostly for Dilaudid 4mg, Oxycodone 30mg and Percocet 10/325 (Endocet). Inspector R.V.

secured 993 of these prescriptions. Inspector R.V. asked Respondent Abergel do a "Stock on Hand" inventory on brand and generic forms of Dilaudid 4mg, Oxycodone 30mg and Endocet 10/325. He requested the last DEA Biennial Inventory.

- 23. Inspector R.V. asked Respondent Abergel if Respondent Druggist had any break-ins or losses. Respondent Abergel provided a "Report of Theft or Loss of Controlled Substances" and the card of the investigator from the local sheriff's department. However, there were no loss of drugs Inspector R.V. was going to audit on the loss report. Respondent Abergel further informed Inspector R.V. that he did not report the loss to the Board.
- 24. Inspector A.N. obtained prescription labels that were not in compliance with pharmacy law and in addition a corrected form that was compliant. Inspector R.V. filled out an Inspection Report, noted the discussed items and requested the following:
  - All invoices from all wholesalers for brand and generic forms Dilaudid 4mg, oxycontin 30mg, and percocet10/325 from 7/8/2010 to 12/18/2012 to be sent to Inspector R.V..
  - Drug utilization report for brand and generic forms of Dilaudid 4mg, Oxycontin 30mg and Percocet 10/325 from 7/8/2010 - 12/18/2012 to include name and addresses of patients and doctors, RX no., date, drug, quantity, days supply and method of payment.
  - Control substance log (daily logs) for all control substances from 7/8/2010 to
     12/18/2012 to include names and addresses of patients and doctors, rx no, rx date,
     drug, quantity, days' supply and method of payment to be in excel format.
  - All DUR and logs to be on separate cd's or flash drives (2 copies of each) to be sent, and all invoices from all wholesalers for brand and generic forms for Dilaudid 4mg, to Inspector R.V., PO Box 594, San Clemente, CA 92674 by 12/22/2012.
- 25. Inspector R.V. issued Official Receipt # 200191 for the secured documents, and the inspectors left.

- 26. On March 28, 2013, Inspector R.V. sent out letters to 5 patients of Respondent Druggist requesting an interview. All 5 letters were returned as undeliverable (Not included in report, but held in evidence).
- 27. On or about January 4, 2013, Inspector R.V. received the requested documents from The Druggist which consisted of:
  - Cover letter from Respondent Abergel and his wife (Exhibit 8, 4 pages). Respondent Abergel stated the doctor's office asked him to deliver the prescriptions to their office after a driver delivered them to the pharmacy. Later it was changed to a driver delivering the prescription documents and then picking up the filled prescriptions the next day. Respondent Abergel stated his wife called the DEA and the state Board.
  - Mrs. Abergel stated she and her husband met with the Pain Management Physicians in Van Nuys and they were asked to deliver prescriptions to their office. The wife then called the DEA and the state board and was informed nothing prohibited delivering to a doctor's office.
  - Last page of the document was the corrections they made as a result of the inspection.
  - I received the flash drives with DURs for Dilaudid 4mg, oxycodone 30 and Endocet 10/325 (not included in report, but held in evidence).
  - The Druggist also provided invoices from H.D. Smith and Valley Wholesale for the 3 drugs.
- 28. Inspector R.V. printed out the DUR's from the flash drive provided by Respondent Druggist. That document showed Respondent Druggist dispensed 16,640 tablets of Dilaudid 4mg and 2,575 tablets of generic Hydromorphone 4mg for a total of 19,215 tablets; 249,152 tablets of Oxycodone 30mg and 53,516 tablets of Endocet 10/325 from 7/8/2010 to 12/18/2012.
- 29. Inspector R.V. entered the invoices provided by Respondent Druggist from H.D. Smith and Valley Wholesale for the 3 drugs onto a spread sheet which showed Respondent Druggist purchased 18,000 tablets of Dilaudid 4mg, 224,500 tablets of Oxycodone 30mg and 50,400 tablets of Endocet 10/325 from 7/8/2010 to 12/18/2012.

	30.	On June 30, 2014 and July 24, 2014, Inspector R.V. forwarded letters to H.D. Smith
and V	alley	Wholesale requesting records of sales to Respondent Druggist for Dilaudid 4mg brand
and g	eneric	, Oxycodone 30mg and Endocet $10/325$ from $7/8/2010 - 12/18/2012$ . Her further sen
anoth	er lett	er to H.D. Smith on July 29, 2014 requesting additional information.

- 31. On or about July 20, 2014, Inspector R.V. received the requested records from Valley Wholesale, in Excel format, which showed Respondent Druggist purchased 15, 100 tablets of Dilaudid 4mg, 44,500 tablets of Endocet 10/325, 2,400 tablets of Hydromorphone 4mg, 54,500 tablets of Oxycodone 30mg (bottles of 100), 90,500 tablets of Oxycodone 30mg (bottles of 500), an additional 55,700 tablets of Oxycodone 30mg (Mallinckrodt) and 400 Oxycodone Acetaminophen 10/325.
- 32. On or about July 29, 2014, Inspector R.V. received the reply from H.D. Smith in Excel format which showed Respondent Druggist purchased 19,300 tablets of Dilaudid 4mg, 248,800 tablets of Oxycodone 30mg and 54,100 tablets of Endocet 10/325.
- 33. When compared to the invoices provided by Respondent Druggist, it revealed that Respondent Druggist did not provide invoices for 800 tablets of Dilaudid 4mg, 24,300 tablets of oxycodone 30mg and 3,700 tablets of Endocet 10/325.
- 34. Using the DEA inventory of 7/8/2010 as the initial amount, the invoices provided by the wholesalers as the amount ordered, the DUR's provided by Respondent Druggist as the amount dispensed and the Stock on Hand inventory as the ending inventory, Inspector R.V. performed a "Selected Drug Audit Summary" which Respondent Druggist did not account for 74 Dilaudid 4mg, 164 Oxycodone 30mg and 584 Endocet 10/325.
- 35. Examination of the 993 prescription secured from Respondent Druggist showed the majority were written by:
  - Dr. C. A., located in Inglewood
  - Dr. R. C., located in Studio City
  - Dr. B. O., located at 7035 Reseda Blvd., Reseda
  - Dr. J. G., located at 7035 Reseda Blvd., Reseda
  - Dr. R. L., located at 7035 Reseda Blvd., Reseda

	1	
	2	
	3	
	4	
	5	
	6	
	7	
	8	
	9	
1	0	
1	1	
1	2	
1	3	
1	4	
1	5	
1	6	
1	7	
1	8	
1	9	
2	0	
2	1	
2	2	
2	3	
2	4	

26

27

•	Dr.	R.	S.,	located	at 71	035	Reseda	Blvd.,	Reseda

- Dr. H. S., located in Los Angeles
- Inspector R.V. included samples of the secured prescriptions from The Druggist: 36.
  - On April 29, 2011, there were 12 prescriptions from Drs. B.O. and Dr. J.G. for Endocet 10/325, Oxycodone 30mg and Dilaudid 4mg. Patients came from Los Angeles, Canoga Park, Burbank, N. Hollywood, and Panorama City. The prescription numbers were in sequence showing the patients or prescriptions came in the same time.
  - On May 6, 2011, there were 14 prescriptions from Drs. J.G., R.L., and B.O. for Oxycodone 30mg, Endocet 10/325, and Dilaudid 4mg. Patients were from Los Angeles, Beverly Hills, and North Hollywood. Prescriptions were in sequence.
  - On June 6, 2011, there were 20 prescriptions from Drs. J.G., R.L., B.O. for Oxycodone 30mg and Endocet 10/325. Patients were from S. Los Angeles, Rialto, Hacienda Heights, Gardena, California City, Venice and Moreno Valley. Prescription numbers were in sequence.
  - On July 21, 2011, there were 17 prescriptions from Drs. B.O., J.G., R.L., and R.S. (all same office address) for Endocet 10/325, Lortabs, Hydrocodone/apap 10/325, Oxycodone 30mg, Norco, and Dilaudid 4mg. Patients came from S. Los Angeles, N. Hollywood, Sylmar, S. Pasadena, Mission Viejo, Palm Springs and Norwalk. Prescriptions were in sequence.
  - On August 16, 2011, there were 16 prescriptions from Drs. J.G., R.L., R.S., and B.O. for oxycodone 30mg, Endocet 10/325 and Dilaudid 4mg. Patients were from S. Los Angeles, Inglewood, Santa Monica, Pomona, Compton, Manhattan Beach, Paramount, and Glendale. Prescriptions were in sequence.
  - On January 30, 3012, there were 12 prescriptions from Drs. C.A. and H.S. for Oxycodone 30mg. Each doctor had the same dosage for his patient. The patients came from Compton, S. Los Angeles, Northridge, Long Beach, Sylmar, Mission Hills and Inglewood. The prescription numbers were in sequence.

•	On February 2, 2012, there were 11 prescriptions from Dr. C.A. for Oxycodone
	30mg. All of the patients had the same dosage.

- On February 9, 2012, there were 10 prescriptions from Dr. R.C. for Oxycodone
   30mg. Patients were from Los Angeles, Inglewood and Sylmar. The prescription numbers were in sequence.
- 37. In summary, Respondent Druggist filled these prescriptions when there too many red flags for the pharmacist not to notice that these prescriptions were not for a legitimate medical purpose:
  - Doctors were out of area and patients were as far as Palm Springs.
  - Patients were given the same medication and the same dosage.
  - Drivers provided no identification and no proof they were working for the doctor.
  - The Druggist did not obtain CURES reports for these patients to determine if they were doctor shopping, obtaining prescriptions from multiple pharmacies.
- 38. Inspector R.V. obtained some patient profiles (Respondent Druggist DUR's) and Patient Activity Reports (PAR) from CURES on patients of Respondent Druggist which showed:
  - Patient profile for R.A located in West Hollywood showed from 5/1/2012 to 7/242012 obtained prescriptions for Oxycodone 30mg from 3 doctors as far away as Corona. The PAR showed R.A. obtained prescriptions for Oxycodone from 8 doctors and 7 pharmacies within a year.
  - Respondent Druggist's own patient profile for R.A. #2 showed in 4 months he had obtained Oxycodone 30mg from 4 doctors from Woodland Hills to Corona.
  - PAR for A.C. showed he obtained Oxycodone 30mg from 3 pharmacies and 4 doctors within 11 months.
  - PAR for D.G. living in Long Beach showed he obtained Oxycodone and other controlled substances from 7 pharmacies (from Long Beach, Ontario to Valencia) and from 7 doctors.

26

- PAR for S.H. living in Los Angeles showed the patient obtained Oxycodone 30mg
   from 9 pharmacies from Los Angeles to Desert Hot Springs and 9 doctors from Los
   Angeles to Corona, while obtaining Oxycodone 30mg from Respondent Druggist.
- Respondent Druggist's own patient profile for H.L. living in Lancaster, had Rx # 60232, dated 12/1/2011 for 120 Oxycodone 30mg (30 days' supply) by Dr. C. and Rx # 60925, dated 12/20/2011 for 180 oxycodone (30 DS) by Dr. A., 11 days early. The PAR for H.L. shows the patient went to 9 pharmacies from Los Angeles to Lancaster and 7 doctors from Los Angeles to Corona while obtaining prescriptions from Respondent Druggist.
- The PAR for A.J. living in Riverside shows the patient went to 5 pharmacies from Long Beach, Gardena to Valencia and to 4 doctors from Long Beach, Panorama City to Los Angeles while obtaining controlled substances from Respondent Druggist.
- The PAR for B.M. (Exhibit 32, 1 page) shows the patient had Rx # 541124, dated 1/6/2012 for 180 oxycodone 30mg (30ds) at another pharmacy by Dr. A.. The Druggist filled Rx # 62258, dated 1/28/2012 for 180 Oxycodone 30mg by Dr. M.S., 8 days early. The patient had Rx # 54424, dated 3/2/2012 for 180 Oxycodone 30mg (30 DS) at another pharmacy by Dr. A. Respondent Druggist filled Rx # 64202, dated 3/12/2012 for 150 Oxycodone 30mg by Dr. S., 20 days early.
- The Par for N.E. shows the patient went to 4 pharmacies and 6 doctors while obtaining prescriptions for controlled substances while obtaining prescriptions from Respondent Druggist.
- The PAR for J.O., living in N. Hollywood, had Rx # 348972, written by Dr. G. dated 1/7/2011 for 90 Oxycodone 30mg (30DS) dispensed at another pharmacy.
  Respondent Druggist filled Rx # 46862, dated 1/10/2011, written by Dr. B. for 100 Oxycodone 30 mg (20DS), 23 days early. J.O. had Rx # 353146, dated 2/11/2011, written by Dr. G. for 90 Oxycodone 30mg (30DS). Respondent Druggist filled Rx 48699, dated 2/21/2011, written by Dr. B. for 100 Oxycodone 30mg, 20 days early.

J.O. had Rx # 49276, dated 3/7/2011, written by Dr. B. for 100 Oxycodone 30mg
(20DS) dispensed at Respondent Druggist. J.O had Rx # 356523, dated 3/11/2011,
written by Dr. G. for 90 Oxycodone 30mg (30DS) dispensed at another pharmacy.
J.O. now has 50 day supply of Oxycodone 30mg at home. Respondent Druggist
filled Rx # 49789, dated 3/21/2011, written by Dr. B. for 100 Oxycodone 30mg
(20DS), 40 days early. Further, Respondent Druggist filled Rx # 50328, dated
4/4/2011, written by Dr. Dr. B. for 100 Oxycodone 30mg, over 7 days early. J.O.
had Rx # 274305, dated 1/31/2012, written by Dr. E. for 150 Oxycodone 30mg
(25DS). Respondent Druggist filled Rx # 62922, dated 2/13/2012, written by Dr. G.
for 60 oxycodone 30mg. 12 days early. J.O went to 9 pharmacies from Valencia,
Lancaster to Panorama City and 7 doctors while obtaining prescriptions for
controlled substances from Respondent Druggist.

- 39. Had Respondent Druggist obtained PAR's and reviewed their own patient profiles for these patients they would have noticed the multiple pharmacies, multiple doctors and early refills.
- 40. On August 14, 2014, Inspector R.V. issued a Written Notice for violation of California Code of Regulation sections 1761(a), 1715.6, 1718; Business and Professions section 4081(a) and Health and Safety Code section 11153(a).

# FIRST CAUSE FOR DISCIPLINE

# (Filling of Erroneous or Uncertain Prescriptions and Failure to Assume Co-Responsibility in Legitimacy of a Prescription)

41. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under California Code of Regulations section 1761, subd. (a) in conjunction with Health and Safety Code section 11153, subd (a), and Bus. Prof. C. §§4113, 4156, 4301, 4301(d), 4301 (j), 4301(o), 4302, 4035 and 4306.5, in conjunction with Health & Safety C. §11153, subdivision (a), and pursuant to Vermont & 110th Medical Arts v. Board of Pharmacy (1981) 125 Cal.App.3d 19 (hereinafter referred as Vermont), pursuant to Sternberg v. Board of Pharmacy (2015) 239 Cal. App. 4th 1159 (hereinafter referred as Sternberg), and pursuant to the Board of Pharmacy's Precedential Decision No. 2013-01 (Board of Pharmacy v. Pacifica Pharmacy Corporation, et

al., (2012) Case No. 3802, OAH No. 2011010644) (hereinafter referred as Pacifica) on the grounds of unprofessional conduct because Respondents failed to exercise or implement their best professional judgment or their corresponding responsibility to ensure that controlled substances are dispensed for a legitimate medical purpose, in that Respondents compounded or dispensed prescriptions which contain significant error, omission, irregularity, uncertainty, ambiguity or alteration. Respondents failed to contact the prescriber to obtain the information needed to validate the prescription. Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose and in filling these prescriptions. Respondent Druggist filled prescriptions for habitual doctor shoppers and erroneous/uncertain prescriptions as set forth in paragraphs 56 and 57. J.O went to 9 pharmacies from Valencia, Lancaster to Panorama City and 7 doctors while obtaining prescriptions for controlled substances from The Druggist. Filling prescriptions for controlled substances for patients from all areas of Southern California coming in at the same time and also from doctors out of the area. These prescriptions for controlled substance were filled and provided to un-identified, unauthorized drivers without confirming with the patient.

42. Complainant refers to and by this reference incorporates the allegations set forth above in paragraphs 21-40, inclusive, as though set forth fully.

# SECOND CAUSE FOR DISCIPLINE

# (Failure to Keep Complete Accountability)

- 43. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under California Code of Regulations section 1718, in conjunction with Code sections 4081 and 4332, and California Federal Regulations, Title 21, section 1304, and Bus. Prof. C. §4113, and Stenberg, in that based on records from 7/8/2010 12/18/2012, Respondents failed to account for 74 tablets of Dilaudid 4mg, 164 tablets of Oxycodone 30mg and 584 tablets of Endocet 10/325.
- 44. Complainant refers to and by this reference incorporates the allegations set forth above in paragraphs 21-40, inclusive, as though set forth fully.

# 

THIRD CAUSE FOR DISCIPLINE

#### (Failure to Notify Board of Loss of Controlled Substances)

- 45. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action Under California Code of Regulations, Title 16, section 1715.6, and Bus. Prof. C. §4113, and Stenberg, in that Respondents failed to report the loss of 400 Hydrocodone/apap 5/500, 200 Hydrocodone/apap 7.5/750, 480 Hydrocodone/apap 10/650, 180 Hydrocodone/apap 10/325 and 260 Hydrocodone/apap 10/325 on 9/3/2012.
- 46. Complainant refers to and by this reference incorporates the allegations set forth above in paragraphs 21-40, inclusive, as though set forth fully.

#### OTHER MATTERS

- 47. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 50146 issued to The Druggist Inc., The Druggist Inc. shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if it is revoked.
- 48. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 50146 issued to The Druggist Inc. while Joel Abergel has been an officer and owner and had knowledge of or knowingly participated in any conduct for which the licensee was disciplined, Joel Abergel shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if it is revoked.

#### **DISCIPLINE CONSIDERATIONS**

49. To determine the degree of discipline, if any, to be imposed on Respondent Abergel, Complainant alleges that on or about October 31, 2007, the Board of Pharmacy issued a Citation to Respondent Abergel in Case No. CI 2007 34523 in the amount of \$4,000.00 for violating California Code of Regulations, title 16, section 1714, subdivision (d) [theft policy]. That Citation is now final and is incorporated by reference as if fully set forth.

2

3 4

5

7

8

6

9

10

11 12

13

14 15

16

17

18 19

20

21

22

23 24

25

26

27

28

#### **PRAYER**

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- Revoking or suspending Pharmacy Permit Number PHY 50146 issued to The 1. Druggist, Inc.;
- Revoking or suspending Pharmacist License Number RPH 41192 issued to Joel 2. Abergel aka Joelle Abergel;
- 3. Prohibiting The Druggist Inc. from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if Pharmacy Permit Number 50146 issued to The Druggist Inc. is revoked;
- Prohibiting Joel Abergel from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if Pharmacy Permit Number 50146 issued to The Druggist Inc. is revoked;
- 5. Ordering The Druggist, Inc. and Joel Abergel aka Joelle Abergel to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; and
  - Taking such other and further action as deemed necessary and proper. 6.

3/17/18

Executive Officer Board of Pharmacy

Department of Consumer Affairs

State of California Complainant

LA2014512855 52580243.docx

1	XAVIER BECERRA	
2	Attorney General of California MARC D. GREENBAUM	
	Supervising Deputy Attorney General	
3	MORGAN MALEK Deputy Attorney General	
4	State Bar No. 223382 300 So. Spring Street, Suite 1702	
5	Los Angeles, CA 90013 Telephone: (213) 897-2643	
- 6	Facsimile: (213) 897-2804 Attorneys for Complainant	
7	· · · · · · · · · · · · · · · · · · ·	
8	BEFOR BOARD OF F	
9	DEPARTMENT OF CO STATE OF C	
10		1
11	In the Matter of the Accusation Against:	Case No. 5321
12	THE DRUGGIST, INC.,	
13	JOEL ABERGEL, OWNER 27867 Smyth Drive	FIRST AMENDED ACCUSATION
14	Valencia, CA 91355	
15	Pharmacy Permit No. PHY 50146,	
16	and	
17	JOEL ABERGEL AKA JOELLE	
18	ABERGEL	
19	23905 Lakeside Road Santa Clarita, CA 91355	
20	Pharmacist License No. RPH 41192	
21	Respondents.	· .
22		
23	Complainant alleges:	
24	PART	<u> TIES</u>
25	1. Virginia Herold ("Complainant") brin	gs this Accusation solely in her official capacit
26	as the Executive Officer of the Board of Pharmac	y, Department of Consumer Affairs.
27	2. On or about June 10, 2010, the Board	of Pharmacy issued Pharmacy Permit Number
28	PHY 50146 to The Druggist Inc. to do business as	s The Druggist Inc. ("Respondent Pharmacy").

11<sup>1</sup>

1314

15

16

17

18 19

20

21

2223

24

25

26

2728

Joel Abergel has been the owner, President, and Pharmacist-in-Charge of Respondent Pharmacy since June 10, 2010. The Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein and will expire on June 1, 2016, unless renewed.

3. On or about September 26, 1987, the Board of Pharmacy issued Pharmacist License Number RPH 41192 to Joel Abergel aka Joelle Abergel ("Respondent Abergel"). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on April 30, 2017, unless renewed.

## **JURISDICTION**

- 4. This Accusation is brought before the Board of Pharmacy ("Board"), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.
  - 5. **Section 4300.1** of the Code states:

"The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license."

- 6. Section 4300 of the Code states, in pertinent part:
- "(a) Every license issued may be suspended or revoked.
- "(b) The board shall discipline the holder of any license issued by the board, whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:
  - "(1) Suspending judgment.
  - "(2) Placing him or her upon probation.
  - "(3) Suspending his or her right to practice for a period not exceeding one year.
  - "(4) Revoking his or her license.
- "(5) Taking any other action in relation to disciplining him or her as the board in its discretion may deem proper.

. . . .

"(e) The proceedings under this article shall be conducted in accordance with Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code, and the board shall have all the powers granted therein. The action shall be final, except that the propriety of the action is subject to review by the superior court pursuant to Section 1094.5 of the Code of Civil Procedure."

## STATUTES AND REGULATIONS

- 7. Section 4081, subdivision (a) of the Code states:
- "(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall be kept by every manufacturer, wholesaler, third-party logistics provider, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous drugs or dangerous devices."
  - 8. Section 4301 of the Code states, in pertinent part:

"The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

. . . .

"(j) The violation of any of the statutes of this state, or any other state, or of the United States regulating controlled substances and dangerous drugs.

• • • •

"(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable

federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency. "

- 9. Section 4307, subdivision (a), of the Code states, in pertinent part:
- (a) Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of any partnership, corporation, trust, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control had knowledge of or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, partner, or in any other position with management or control of a licensee as follows:
- (1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.
- (2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.
- (b) "Manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of a license" as used in this section and Section 4308, may refer to a pharmacist or to any other person who serves in such capacity in or for a licensee.
- (c) The provisions of subdivision (a) may be alleged in any pleading filed pursuant to Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code. However, no order may be issued in that case except as to a person who is named in the caption, as to whom the pleading alleges the applicability of this section, and where the person has been given notice of the proceeding as required by Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code. The authority to proceed as provided by this subdivision

shall be in addition to the board's authority to proceed under Section 4339 or any other provision of law.

10. Section 4332, subdivision (a), of the Code states, in pertinent part:

"Any person who fails, neglects, or refuses to maintain the records required by Section 4081 or who, when called upon by an authorized officer of a member of the board, fails, neglects, or refuses to produce or provide the records within a reasonable time, or who willfully produces or furnishes records that are false, is guilty of a misdemeanor.

- 11. Health and Safety Code section 11153 states, in pertinent part:
- "(a) A prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. Except as authorized by this division, the following are not legal prescriptions: (1) an order purporting to be a prescription which is issued not in the usual course of professional treatment or in legitimate and authorized research; or (2) an order for an addict or habitual user of controlled substances, which is issued not in the course of professional treatment or as part of an authorized narcotic treatment program, for the purpose of providing the user with controlled substances, sufficient to keep him or her comfortable by maintaining customary use."
- 12. California Code of Regulations, title 16, section 1715.6 states, "[t]he owner shall report to the Board within thirty (30) days of discovery of any loss of the controlled substances, including their amounts and strengths."
  - 13. California Code of Regulations, title 16, section 1718 states:

"'Current Inventory' as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

"The controlled substances inventories required by Title 21, CFR, Section 1304 shall be available for inspection upon request for at least 3 years after the date of the inventory."

14. California Code of Regulations, title 16, section 1761 states:

- "(a) No pharmacist shall compound or dispense any prescription which contains any significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any such prescription, the pharmacist shall contact the prescriber to obtain the information needed to validate the prescription.
- "(b) Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose."
- 15. Code of Federal Regulations, title 21, section 1304.04, subdivision (h), states in pertinent part:
- "(h) Each registered pharmacy shall maintain the inventories and records of controlled substances as follows:
- "(1) Inventories and records of all controlled substances listed in Schedule I and II shall be maintained separately from all other records of the pharmacy.
- "(2) Paper prescriptions for Schedule II controlled substances shall be maintained at the registered location in a separate prescription file.
- "(3) Inventories and records of Schedules III, IV, and V controlled substances shall be maintained either separately from all other records of the pharmacy or in such form that the information required is readily retrievable from ordinary business records of the pharmacy."

## CONTROLLED SUBSTANCES/DANGEROUS DRUGS

- 16. **Hydromorphone, the generic name for Dilaudid**, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(J) and is a dangerous drug pursuant to Code section 4022.
- 17. Hydrocodone and acetaminophen ("hydrocodone/apap"), the generic name for Norco and Lortab, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (e)(4) and is a dangerous drug pursuant to Code section 4022. As of October 6, 2014, hydrocodone/apap became a Schedule II controlled substance pursuant to United States Code, title 21, section 812.

18. Oxycodone, the generic name for Oxycontin, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M) and is a dangerous drug pursuant to Code section 4022.

19. Oxycodone and acetaminophen, the generic name for Percocet and Endocet, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M), and is a dangerous drug pursuant to Code section 4022.

## COST RECOVERY

20. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case, with failure of the licentiate to comply subjecting the license to not being renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be included in a stipulated settlement.

## **BOARD'S INSPECTION OF DECEMBER 2012**

- 21. On 12/19/2012, Inspector A.N. and Inspector R.V. traveled to Respondent Pharmacy. Respondent Abergel, and Pharmacy Technicians R.E. and J.R. were present. The inspectors explained to Respondent Abergel that they were there to perform a routine inspection and request and pick up some documents.
- 22. Inspector R.V. proceeded to a perform a physical inspection of the pharmacy and reviewed the prescription files while Inspector A.N. inspected the compounding area. Inspector R.V. examined the Schedule II prescription files and noticed a large number of the prescriptions were from patients out of the area, were mainly from 4 5 doctors out of the area and were filled in sequence, meaning filled one right after the other. He questioned Respondent Abergel about these prescriptions and asked if he saw each patient in the pharmacy. Respondent Abergel informed Inspector R.V. some of the patients he never saw nor provided consultation in person for new prescriptions dispensed. The prescriptions were given to him by "drivers". Respondent Abergel did not have any copies of any type of identification for the drivers. The prescriptions were mostly for Dilaudid 4mg, Oxycodone 30mg and Percocet 10/325 (Endocet). Inspector R.V.

secured 993 of these prescriptions. Inspector R.V. asked Respondent Abergel do a "Stock on Hand" inventory on brand and generic forms of Dilaudid 4mg, Oxycodone 30mg and Endocet 10/325. He requested the last DEA Biennial Inventory.

- 23. Inspector R.V. asked Respondent Abergel if Respondent Druggist had any break-ins or losses. Respondent Abergel provided a "Report of Theft or Loss of Controlled Substances" and the card of the investigator from the local sheriff's department. However, there were no loss of drugs Inspector R.V. was going to audit on the loss report. Respondent Abergel further informed Inspector R.V. that he did not report the loss to the Board.
- 24. Inspector A.N. obtained prescription labels that were not in compliance with pharmacy law and in addition a corrected form that was compliant. Inspector R.V. filled out an Inspection Report, noted the discussed items and requested the following:
  - All invoices from all wholesalers for brand and generic forms Dilaudid 4mg, oxycontin 30mg, and percocet10/325 from 7/8/2010 to 12/18/2012 to be sent to Inspector R.V..
  - Drug utilization report for brand and generic forms of Dilaudid 4mg, Oxycontin 30mg and Percocet 10/325 from 7/8/2010 - 12/18/2012 to include name and addresses of patients and doctors, RX no., date, drug, quantity, days supply and method of payment.
  - Control substance log (daily logs) for all control substances from 7/8/2010 to
     12/18/2012 to include names and addresses of patients and doctors, rx no, rx date,
     drug, quantity, days' supply and method of payment to be in excel format.
  - All DUR and logs to be on separate cd's or flash drives (2 copies of each) to be sent, and all invoices from all wholesalers for brand and generic forms for Dilaudid 4mg, to Inspector R.V., PO Box 594, San Clemente, CA 92674 by 12/22/2012.
- 25. Inspector R.V. issued Official Receipt # 200191 for the secured documents, and the inspectors left.

- 26. On March 28, 2013, Inspector R.V. sent out letters to 5 patients of Respondent Druggist requesting an interview. All 5 letters were returned as undeliverable (Not included in report, but held in evidence).
- 27. On or about January 4, 2013, Inspector R.V. received the requested documents from The Druggist which consisted of:
  - Cover letter from Respondent Abergel and his wife (Exhibit 8, 4 pages). Respondent Abergel stated the doctor's office asked him to deliver the prescriptions to their office after a driver delivered them to the pharmacy. Later it was changed to a driver delivering the prescription documents and then picking up the filled prescriptions the next day. Respondent Abergel stated his wife called the DEA and the state Board.
  - Mrs. Abergel stated she and her husband met with the Pain Management Physicians in Van Nuys and they were asked to deliver prescriptions to their office. The wife then called the DEA and the state board and was informed nothing prohibited delivering to a doctor's office.
  - Last page of the document was the corrections they made as a result of the inspection.
  - I received the flash drives with DURs for Dilaudid 4mg, oxycodone 30 and Endocet 10/325 (not included in report, but held in evidence).
  - The Druggist also provided invoices from H.D. Smith and Valley Wholesale for the 3 drugs.
- 28. Inspector R.V. printed out the DUR's from the flash drive provided by Respondent Druggist. That document showed Respondent Druggist dispensed 16,640 tablets of Dilaudid 4mg and 2,575 tablets of generic Hydromorphone 4mg for a total of 19,215 tablets; 249,152 tablets of Oxycodone 30mg and 53,516 tablets of Endocet 10/325 from 7/8/2010 to 12/18/2012.
- 29. Inspector R.V. entered the invoices provided by Respondent Druggist from H.D. Smith and Valley Wholesale for the 3 drugs onto a spread sheet which showed Respondent Druggist purchased 18,000 tablets of Dilaudid 4mg, 224,500 tablets of Oxycodone 30mg and 50,400 tablets of Endocet 10/325 from 7/8/2010 to 12/18/2012.

	30.	On June 30, 2014 and July 24, 2014, Inspector R.V. forwarded letters to H.D. Smith
and \	Valley	Wholesale requesting records of sales to Respondent Druggist for Dilaudid 4mg bran
and g	generic	c, Oxycodone 30mg and Endocet $10/325$ from $7/8/2010 - 12/18/2012$ . Her further set
anotl	er lett	er to H.D. Smith on July 29, 2014 requesting additional information.

- 31. On or about July 20, 2014, Inspector R.V. received the requested records from Valley Wholesale, in Excel format, which showed Respondent Druggist purchased 15, 100 tablets of Dilaudid 4mg, 44,500 tablets of Endocet 10/325, 2,400 tablets of Hydromorphone 4mg, 54,500 tablets of Oxycodone 30mg (bottles of 100), 90,500 tablets of Oxycodone 30mg (bottles of 500), an additional 55,700 tablets of Oxycodone 30mg (Mallinckrodt) and 400 Oxycodone Acetaminophen 10/325.
- 32. On or about July 29, 2014, Inspector R.V. received the reply from H.D. Smith in Excel format which showed Respondent Druggist purchased 19,300 tablets of Dilaudid 4mg, 248,800 tablets of Oxycodone 30mg and 54,100 tablets of Endocet 10/325.
- 33. When compared to the invoices provided by Respondent Druggist, it revealed that Respondent Druggist did not provide invoices for 800 tablets of Dilaudid 4mg, 24,300 tablets of oxycodone 30mg and 3,700 tablets of Endocet 10/325.
- 34. Using the DEA inventory of 7/8/2010 as the initial amount, the invoices provided by the wholesalers as the amount ordered, the DUR's provided by Respondent Druggist as the amount dispensed and the Stock on Hand inventory as the ending inventory, Inspector R.V. performed a "Selected Drug Audit Summary" which Respondent Druggist did not account for 74 Dilaudid 4mg, 164 Oxycodone 30mg and 584 Endocet 10/325.
- 35. Examination of the 993 prescription secured from Respondent Druggist showed the majority were written by:
  - Dr. C. A., located in Inglewood
  - Dr. R. C., located in Studio City
  - Dr. B. O., located at 7035 Reseda Blvd., Reseda
  - Dr. J. G., located at 7035 Reseda Blvd., Reseda
  - Dr. R. L., located at 7035 Reseda Blvd., Reseda

- Dr. R. S., located at 7035 Reseda Blvd., Reseda
- Dr. H. S., located in Los Angeles
- 36. Inspector R.V. included samples of the secured prescriptions from The Druggist:
  - On April 29, 2011, there were 12 prescriptions from Drs. B.O. and Dr. J.G. for
    Endocet 10/325, Oxycodone 30mg and Dilaudid 4mg. Patients came from Los
    Angeles, Canoga Park, Burbank, N. Hollywood, and Panorama City. The
    prescription numbers were in sequence showing the patients or prescriptions came
    in the same time.
  - On May 6, 2011, there were 14 prescriptions from Drs. J.G., R.L., and B.O. for
    Oxycodone 30mg, Endocet 10/325, and Dilaudid 4mg. Patients were from Los
    Angeles, Beverly Hills, and North Hollywood. Prescriptions were in sequence.
  - On June 6, 2011, there were 20 prescriptions from Drs. J.G., R.L., B.O. for
     Oxycodone 30mg and Endocet 10/325. Patients were from S. Los Angeles, Rialto,
     Hacienda Heights, Gardena, California City, Venice and Moreno Valley.
     Prescription numbers were in sequence.
  - On July 21, 2011, there were 17 prescriptions from Drs. B.O., J.G., R.L., and R.S. (all same office address) for Endocet 10/325, Lortabs, Hydrocodone/apap 10/325,
     Oxycodone 30mg, Norco, and Dilaudid 4mg. Patients came from S. Los Angeles,
     N. Hollywood, Sylmar, S. Pasadena, Mission Viejo, Palm Springs and Norwalk.
     Prescriptions were in sequence.
  - On August 16, 2011, there were 16 prescriptions from Drs. J.G., R.L., R.S., and B.O. for oxycodone 30mg, Endocet 10/325 and Dilaudid 4mg. Patients were from S. Los Angeles, Inglewood, Santa Monica, Pomona, Compton, Manhattan Beach, Paramount, and Glendale. Prescriptions were in sequence.
  - On January 30, 3012, there were 12 prescriptions from Drs. C.A. and H.S. for
     Oxycodone 30mg. Each doctor had the same dosage for his patient. The patients
     came from Compton, S. Los Angeles, Northridge, Long Beach, Sylmar, Mission
     Hills and Inglewood. The prescription numbers were in sequence.

27

28

- On February 2, 2012, there were 11 prescriptions from Dr. C.A. for Oxycodone 30mg. All of the patients had the same dosage.
- On February 9, 2012, there were 10 prescriptions from Dr. R.C. for Oxycodone
   30mg. Patients were from Los Angeles, Inglewood and Sylmar. The prescription numbers were in sequence.
- 37. In summary, Respondent Druggist filled these prescriptions when there too many red flags for the pharmacist not to notice that these prescriptions were not for a legitimate medical purpose:
  - Doctors were out of area and patients were as far as Palm Springs.
  - Patients were given the same medication and the same dosage.
  - Drivers provided no identification and no proof they were working for the doctor.
  - The Druggist did not obtain CURES reports for these patients to determine if they were doctor shopping, obtaining prescriptions from multiple pharmacies.
- 38. Inspector R.V. obtained some patient profiles (Respondent Druggist DUR's) and Patient Activity Reports (PAR) from CURES on patients of Respondent Druggist which showed:
  - Patient profile for R.A located in West Hollywood showed from 5/1/2012 to 7/242012 obtained prescriptions for Oxycodone 30mg from 3 doctors as far away as Corona. The PAR showed R.A. obtained prescriptions for Oxycodone from 8 doctors and 7 pharmacies within a year.
  - Respondent Druggist's own patient profile for R.A. #2 showed in 4 months he had obtained Oxycodone 30mg from 4 doctors from Woodland Hills to Corona.
  - PAR for A.C. showed he obtained Oxycodone 30mg from 3 pharmacies and 4 doctors within 11 months.
  - PAR for D.G. living in Long Beach showed he obtained Oxycodone and other controlled substances from 7 pharmacies (from Long Beach, Ontario to Valencia) and from 7 doctors.

- PAR for S.H. living in Los Angeles showed the patient obtained Oxycodone 30mg from 9 pharmacies from Los Angeles to Desert Hot Springs and 9 doctors from Los Angeles to Corona, while obtaining Oxycodone 30mg from Respondent Druggist.
- Respondent Druggist's own patient profile for H.L. living in Lancaster, had Rx #
  60232, dated 12/1/2011 for 120 Oxycodone 30mg (30 days' supply) by Dr. C. and
  Rx # 60925, dated 12/20/2011 for 180 oxycodone (30 DS) by Dr. A., 11 days early.
  The PAR for H.L. shows the patient went to 9 pharmacies from Los Angeles to
  Lancaster and 7 doctors from Los Angeles to Corona while obtaining prescriptions
  from Respondent Druggist.
- The PAR for A.J. living in Riverside shows the patient went to 5 pharmacies from Long Beach, Gardena to Valencia and to 4 doctors from Long Beach, Panorama City to Los Angeles while obtaining controlled substances from Respondent Druggist.
- The PAR for B.M. (Exhibit 32, 1 page) shows the patient had Rx # 541124, dated 1/6/2012 for 180 oxycodone 30mg (30ds) at another pharmacy by Dr. A.. The Druggist filled Rx # 62258, dated 1/28/2012 for 180 Oxycodone 30mg by Dr. M.S., 8 days early. The patient had Rx # 54424, dated 3/2/2012 for 180 Oxycodone 30mg (30 DS) at another pharmacy by Dr. A. Respondent Druggist filled Rx # 64202, dated 3/12/2012 for 150 Oxycodone 30mg by Dr. S., 20 days early.
- The Par for N.E. shows the patient went to 4 pharmacies and 6 doctors while obtaining prescriptions for controlled substances while obtaining prescriptions from Respondent Druggist.
- The PAR for J.O., living in N. Hollywood, had Rx # 348972, written by Dr. G. dated 1/7/2011 for 90 Oxycodone 30mg (30DS) dispensed at another pharmacy.
  Respondent Druggist filled Rx # 46862, dated 1/10/2011, written by Dr. B. for 100 Oxycodone 30 mg (20DS), 23 days early. J.O. had Rx # 353146, dated 2/11/2011, written by Dr. G. for 90 Oxycodone 30mg (30DS). Respondent Druggist filled Rx 48699, dated 2/21/2011, written by Dr. B. for 100 Oxycodone 30mg, 20 days early.

J.O. had Rx # 49276, dated 3/7/2011, written by Dr. B. for 100 Oxycodone 30mg				
(20DS) dispensed at Respondent Druggist. J.O had Rx $\#$ 356523, dated $3/11/2011$ ,				
written by Dr. G. for 90 Oxycodone 30mg (30DS) dispensed at another pharmacy.				
J.O. now has 50 day supply of Oxycodone 30mg at home. Respondent Druggist				
filled Rx # 49789, dated 3/21/2011, written by Dr. B. for 100 Oxycodone 30mg				
(20DS), 40 days early. Further, Respondent Druggist filled Rx # 50328, dated				
4/4/2011, written by Dr. Dr. B. for 100 Oxycodone 30mg, over 7 days early. J.O.				
had Rx # 274305, dated 1/31/2012, written by Dr. E. for 150 Oxycodone 30mg				
(25DS). Respondent Druggist filled Rx # 62922, dated 2/13/2012, written by Dr. G.				
for 60 oxycodone 30mg. 12 days early. J.O went to 9 pharmacies from Valencia,				
Lancaster to Panorama City and 7 doctors while obtaining prescriptions for				
controlled substances from Respondent Druggist.				

- 39. Had Respondent Druggist obtained PAR's and reviewed their own patient profiles for these patients they would have noticed the multiple pharmacies, multiple doctors and early refills.
- 40. On August 14, 2014, Inspector R.V. issued a Written Notice for violation of California Code of Regulation sections 1761(a), 1715.6, 1718; Business and Professions section 4081(a) and Health and Safety Code section 11153(a).

#### FIRST CAUSE FOR DISCIPLINE

# (Filling of Erroneous or Uncertain Prescriptions and Failure to Assume Co-Responsibility in Legitimacy of a Prescription)

41. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under California Code of Regulations section 1761, subd. (a) in conjunction with Health and Safety Code section 11153, subd. (a) in that Respondents compounded or dispensed prescriptions which contain significant error, omission, irregularity, uncertainty, ambiguity or alteration. Respondents failed to contact the prescriber to obtain the information needed to validate the prescription. Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose and in filling these

prescriptions. Respondent Druggist filled prescriptions for habitual doctor shoppers and erroneous/uncertain prescriptions as set forth in paragraphs 56 and 57. J.O went to 9 pharmacies from Valencia, Lancaster to Panorama City and 7 doctors while obtaining prescriptions for controlled substances from The Druggist. Filling prescriptions for controlled substances for patients from all areas of Southern California coming in at the same time and also from doctors out of the area. These prescriptions for controlled substance were filled and provided to unidentified, unauthorized drivers without confirming with the patient.

42. Complainant refers to and by this reference incorporates the allegations set forth above in paragraphs 21-40, inclusive, as though set forth fully.

## SECOND CAUSE FOR DISCIPLINE

## (Failure to Keep Complete Accountability)

- 43. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under California Code of Regulations section 1718, in conjunction with Code sections 4081 and 4332, and California Federal Regulation, Title 21, Section 1304 in that based on records from 7/8/2010 12/18/2012, Respondents failed to account for 74 tablets of Dilaudid 4mg, 164 tablets of Oxycodone 30mg and 584 tablets of Endocet 10/325.
- 44. Complainant refers to and by this reference incorporates the allegations set forth above in paragraphs 21-40, inclusive, as though set forth fully.

## THIRD CAUSE FOR DISCIPLINE

## (Failure to Notify Board of Loss of Controlled Substances)

- 45. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under California Code of Regulations section 1715.6 in that Respondents failed to report the loss of 400 Hydrocodone/apap 5/500, 200 Hydrocodone/apap 7.5/750, 480 Hydrocodone/apap 10/650, 180 Hydrocodone/apap 10/325 and 260 Hydrocodone/apap 10/325 on 9/3/2012.
- 46. Complainant refers to and by this reference incorporates the allegations set forth above in paragraphs 21-40, inclusive, as though set forth fully.

///

28 | ///

#### OTHER MATTERS

- 47. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 50146 issued to The Druggist Inc., The Druggist Inc. shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if it is revoked.
- 48. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 50146 issued to The Druggist Inc. while Joel Abergel has been an officer and owner and had knowledge of or knowingly participated in any conduct for which the licensee was disciplined, Joel Abergel shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if it is revoked.

#### **DISCIPLINE CONSIDERATIONS**

49. To determine the degree of discipline, if any, to be imposed on Respondent Abergel, Complainant alleges that on or about October 31, 2007, the Board of Pharmacy issued a Citation to Respondent Abergel in Case No. CI 2007 34523 in the amount of \$4,000.00 for violating California Code of Regulations, title 16, section 1714, subdivision (d) [theft policy]. That Citation is now final and is incorporated by reference as if fully set forth.

#### PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- 1. Revoking or suspending Pharmacy Permit Number PHY 50146 issued to The Druggist, Inc.;
- 2. Revoking or suspending Pharmacist License Number RPH 41192 issued to Joel Abergel aka Joelle Abergel;
- 3. Prohibiting The Druggist Inc. from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit

1	KAMALA D. HARRIS Attorney General of California			
2 3	ARMANDO ZAMBRANO Supervising Deputy Attorney General NANCY A, KAISER			
4	Deputy Attorney General State Bar No. 192083			
5	300 So. Spring Street, Suite 1702 Los Angeles, CA 90013			
6	Telephone: (213) 897-5794 Facsimile: (213) 897-2804			
7	Attorneys for Complainant			
8	BEFORE THE BOARD OF PHARMACY			
9	DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA			
10 11	In the Matter of the Accusation Against:	Case No. 5321		
12	THE DRUGGIST, INC.,	Case 110. 3321		
13	JOEL ABERGEL, OWNER 27867 Smyth Drive	ACCUSATION		
14	Valencia, CA 91355			
15	Pharmacy Permit No. PHY 50146,			
16	and			
17 18 19	JOEL ABERGEL AKA JOELLE ABERGEL 23905 Lakeside Road Santa Clarita, CA 91355			
20 21	Pharmacist License No. RPH 41192			
22	Respondents.			
23	Complainant alleges:			
24	PAR	TIES		
25	1. Virginia Herold ("Complainant") brings this Accusation solely in her official capacity			
26	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.			
27	2. On or about June 10, 2010, the Board of Pharmacy issued Pharmacy Permit Number PHY 50146 to The Druggist Inc. to do business as The Druggist Inc. ("Respondent Pharmacy").			
28		as the Druggist me. (Respondent Filannacy).		
ı		*		

Joel Abergel has been the owner, President, and Pharmacist-in-Charge of Respondent Pharmacy since June 10, 2010. The Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein and will expire on June 1, 2016, unless renewed.

3. On or about September 26, 1987, the Board of Pharmacy issued Pharmacist License Number RPH 41192 to Joel Abergel aka Joelle Abergel ("Respondent Abergel"). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on April 30, 2017, unless renewed.

#### JURISDICTION |

- 4. This Accusation is brought before the Board of Pharmacy ("Board"), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.
  - 5. Section 4300.1 of the Code states:

"The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license."

- 6. Section 4300 of the Code states, in pertinent part:
- "(a) Every license issued may be suspended or revoked.
- "(b) The board shall discipline the holder of any license issued by the board, whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:
  - "(1) Suspending judgment.
  - "(2) Placing him or her upon probation.
  - "(3) Suspending his or her right to practice for a period not exceeding one year.
  - "(4) Revoking his or her license.
- "(5) Taking any other action in relation to disciplining him or her as the board in its discretion may deem proper.

. . . .

"(e) The proceedings under this article shall be conducted in accordance with Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code, and the board shall have all the powers granted therein. The action shall be final, except that the propriety of the action is subject to review by the superior court pursuant to Section 1094.5 of the Code of Civil Procedure."

## STATUTES AND REGULATIONS

- 7. Section 4081, subdivision (a) of the Code states:
- "(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall be kept by every manufacturer, wholesaler, third-party logistics provider, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous drugs or dangerous devices."
  - 8. Section 4301 of the Code states, in pertinent part:

"The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake.

Unprofessional conduct shall include, but is not limited to, any of the following:

. . . .

"(j) The violation of any of the statutes of this state, or any other state, or of the United States regulating controlled substances and dangerous drugs.

. . . .

"(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable

federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency. "

9. Section 4307, subdivision (a), of the Code states, in pertinent part:

"Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner member, officer, director, associate, or partner of any partnership, corporation, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manager, administrator, owner, member, officer, director, associate, or partner had knowledge or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manger, administrator, owner, member, officer, director, associate, or partner of a licensee as follows:

- (1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.
- (2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated."
  - 10. Health and Safety Code section 11153 states, in pertinent part:
- "(a) A prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. Except as authorized by this division, the following are not legal prescriptions: (1) an order purporting to be a prescription which is issued not in the usual course of professional treatment or in legitimate and authorized research; or (2) an order for an addict or habitual user of controlled substances, which is issued not in the course of professional treatment or as part of an authorized narcotic treatment program, for the purpose of providing the user with controlled substances, sufficient to keep him or her comfortable by maintaining customary use."

- 11. California Code of Regulations, title 16, section 1715.6 states, "[t]he owner shall report to the Board within thirty (30) days of discovery of any loss of the controlled substances, including their amounts and strengths."
  - 12. California Code of Regulations, title 16, section 1718 states:

"'Current Inventory' as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

"The controlled substances inventories required by Title 21, CFR, Section 1304 shall be available for inspection upon request for at least 3 years after the date of the inventory."

- 13. California Code of Regulations, title 16, section 1761 states:
- "(a) No pharmacist shall compound or dispense any prescription which contains any significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any such prescription, the pharmacist shall contact the prescriber to obtain the information needed to validate the prescription.
- "(b) Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose."
- 14. Code of Federal Regulations, title 21, section 1304.04, subdivision (h), states in pertinent part:
- "(h) Each registered pharmacy shall maintain the inventories and records of controlled substances as follows:
- "(1) Inventories and records of all controlled substances listed in Schedule I and II shall be maintained separately from all other records of the pharmacy.
- "(2) Paper prescriptions for Schedule II controlled substances shall be maintained at the registered location in a separate prescription file.
- "(3) Inventories and records of Schedules III, IV, and V controlled substances shall be maintained either separately from all other records of the pharmacy or in such form that the information required is readily retrievable from ordinary business records of the pharmacy."

.

#### CONTROLLED SUBSTANCES/DANGEROUS DRUGS

- 15. Hydromorphone, the generic name for Dilaudid, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(J) and is a dangerous drug pursuant to Code section 4022.
- 16. Hydrocodone and acetaminophen ("hydrocodone/apap"), the generic name for Norco and Lortab, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (e)(4) and is a dangerous drug pursuant to Code section 4022. As of October 6, 2014, hydrocodone/apap became a Schedule II controlled substance pursuant to United States Code, title 21, section 812.
- 17. Oxycodone, the generic name for Oxycontin, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M) and is a dangerous drug pursuant to Code section 4022.
- 18. Oxycodone and acetaminophen, the generic name for Percocet and Endocet, is a Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(M), and is a dangerous drug pursuant to Code section 4022.

#### **COST RECOVERY**

19. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case, with failure of the licentiate to comply subjecting the license to not being renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be included in a stipulated settlement.

#### BACKGROUND FACTS

- 20. Following receipt of an article alleging suspicious activity at a pharmacy in the 27800 block of Smyth Drive in Valencia, CA, on or about December 2012, two Board Inspectors conducted a routine inspection of Respondent Pharmacy.
- 21. A Board Inspector examined the Schedule II prescription files and noticed that a large number of prescriptions, particularly oxycodone 30 mg, Percocet/Endocet 10/325, and Dilaudid

4mg were from out-of-the-area patients and were mainly from the same 7 doctors (Drs. Arnold, Charlap, Onubah, Garfinkel, Lifson, Salari, and Shamlou), who were themselves out-of-the-area. When questioned, Respondent Abergel stated that some of the prescriptions were delivered by "drivers," and he did not have identification from the "drivers,"

- 22. A Board Inspector inquired whether Respondent Pharmacy had experienced any thefts or losses. Respondent Abergel provided the Board Inspector with a "Report of Theft or Loss of Controlled Substances" (DEA Form 106). Respondent Abergel acknowledged that he had not reported the loss to the Board.
- 23. A Board Inspector also gathered documents from Respondent Pharmacy for the time period July 8, 2010 to December 18, 2012, including invoices from wholesalers for the brand and generic forms of Dilaudid 4 mg, Oxycontin 30 mg, and Percocet 10/32, drug utilization reports for those same drugs, and controlled substance daily logs.

#### FIRST CAUSE FOR DISCIPLINE

## (Filling Erroneous Prescriptions and Failure to Assume Co-Responsibility in Legitimacy of Prescriptions)

- 24. Respondent Pharmacy and Respondent Abergel (collectively "Respondents") are subject to disciplinary action under Code section 4301, subdivision (j), in conjunction with Health and Safety Code section 11153, subdivision (a), and Code section 4301, subdivision (o), in conjunction with California Code of Regulations, title 16, section 1761, on the grounds of unprofessional conduct in that in between 2011 and 2012, Respondents failed to assume their corresponding responsibility by dispensing controlled substances to habitual doctor and pharmacy shoppers, by failing to validate the legitimacy of prescriptions, by failing to review patients' drug history, and by dispensing erroneous and/or uncertain prescriptions. The circumstances are as follows:
- 25. Patient R.A. #1: Between May 2012 and October 2012, Respondents dispensed 6 prescriptions for oxycodone 30 mg to R.A. #1 from West Hollywood. The Patient Activity Report ("PAR") showed that R.A. #1 had obtained prescriptions for oxycodone 30 mg from 8 different doctors (ranging from Northridge, Panorama City, and Corona) and 7 different

pharmacies (ranging from Victorville, Visalia, and Santa Ana) between June 2011 and October 2012.

- 26. <u>Patient R.A. #2</u>: Between March 2012 and July 2012, Respondents dispensed prescriptions for oxycodone 30 mg to Patient R.A. # 2 written by 4 different doctors from Woodland Hills, Panorama City, and Corona.
- 27. Patient A.C.: The PAR showed that A.C. had obtained prescriptions for oxycodone 30 mg from 3 doctors (ranging from Northridge to Inglewood) and 3 pharmacies (ranging from Victorville, Westminster, and Valencia) between May 2011 and April 2012.
- 28. Patient D.G.: The PAR showed that D.G., from Long Beach, obtained prescriptions for oxycodone 30 mg and hydrocodone/apap 5/500 and 7.5/750 from 9 doctors and 7 pharmacies (ranging from Huntington Park, Ontario, and Rancho Palos Verdes) between July 2009 and September 2012.
- 29. <u>Patient S.H.</u>: The PAR showed that S.H., from Los Angeles, obtained prescriptions for oxycodone 30 mg from 8 doctors (ranging from Inglewood, Northridge, and Panorama City) and 7 pharmacies (ranging from Alhambra, Westminster, Huntington Beach, and Ridgecrest) between February 2011 and August 2012.
- 30. Patient H.L.: On December 1, 2011, Respondents dispensed RX #60232 from Dr. Cho for 120 tablets of oxycodone 30 mg. On December 20, 2011, Respondent dispensed RX #60925 from Dr. Arnold for 180 tablets of oxycodone 30 mg, which was 11 days early. The PAR showed that H.L., from Lancaster, obtained prescriptions for oxycodone 30 mg and hydrocodone/apap 10/325 and 5/500 from 9 doctors (ranging from Inglewood, Beverly Hills, San Diego, and Corona) and 10 pharmacies (ranging from Inglewood and Ridgecrest) between December 2010 and August 2012.
- 31. Patient A.J.: Between March 2012 and June 2012, Respondents dispensed 4 prescriptions of oxycodone 30 mg to A.J. from 3 different doctors. During this time period, A.J. obtained prescriptions for oxycodone 30 mg from 3 other pharmacies ranging from Long Beach to Gardena.

25

26

27

- 32. Patient B.M.: The PAR showed that B.M. had RX #541123 from Dr. Arnold for 180 tablets of oxycodone 30 mg (30 days supply) filled on January 6, 2012 at another pharmacy. On January 28, 2012, Respondents filled RX #62258 from Dr. Shamlou for 180 tablets of oxycodone 30 mg (30 days supply), which was 8 days early. B.M. had RX #54442 from Dr. Arnold for 180 tablets of oxycodone 30 mg (30 days supply) filled on March 2, 2012 at another pharmacy. On March 12, 2012, Respondents filled RX #64202 from Dr. Sison for 150 tablets of oxycodone 30 mg (30 days supply), which was 20 days early.
- 33. <u>Patient N.E.</u>: The PAR showed that N.E., from Castaic, obtained prescriptions for oxycodone 30 mg from 6 doctors (ranging from Northridge to Modesto) and 4 pharmacies (all in Valencia) between September 2009 and December 2012.
- Patient J.O.: The PAR showed that J.O. had RX #348972 from Dr. Gatus for 90 tablets of oxycodone 30 mg (30 days supply) filled on January 7, 2011 at another pharmacy. On January 10, 2011, Respondents filled RX #46863 from Dr. Borazjani for 100 tablets of oxycodone 30 mg (20 days supply), which was 23 days early. J.O had RX #353146 from Dr. Gatus for 90 tablets of oxycodone 30 mg (30 days supply) filled on February 11, 2011 at another pharmacy. On February 21, 2011, Respondents filled RX #48699 from Dr. Borazjani for 100 tablets of oxycodone mg (15 day supply), which was 20 days early. On March 7, 2011, Respondents filled RX #49276 from Dr. Borazjani for 100 tablets of oxycodone 30 mg (20 days supply). On March 11, 2011, J.O. had RX #356523 from Dr. Gatus for 90 tablets of oxycodone 30 mg (30 day supply) filled at another pharmacy. J.O. now had a 50 day supply of oxycodone 30 mg in his possession. On March 21, 2011, Respondents filled RX #49789 from Dr. Borazjani for 100 tablets of oxycodone 30 mg (20 days supply), which was 40 days early. On April 4, 2011, Respondents filled RX #50328 from Dr. Borazjani for 100 tablets of oxycodone 30 mg (25 days supply), which was 7 days early. On January 31, 2012, J.O. had RX #274305 from Dr. Emenike for 150 tablets of oxycodone 30 mg (25 days supply) filled at another pharmacy. On February 13, 2012, Respondents filled RX #62922 from Dr. Gatus for 60 tablets of oxycodone 30 mg (30 days supply), which was 12 days early.

The PAR also showed that J.O., from North Hollywood, went to 14 different pharmacies (ranging from Simi Valley, Burbank, and Panorama City) and 9 different doctors (ranging from Lancaster to Seal Beach) between November 2009 and February 2012.

- 35. Respondents filled prescriptions for controlled substances from the same several doctors for patients from all areas of Southern California, which were delivered at the same time by unidentified drivers without any patient consultation, as follows:
- (a) On April 29, 2011, there were 12 sequential prescriptions from the offices of Drs. Onubah, Garfinkel, and Lifson for oxycodone 30 mg, Percocet/Endocet 10/325, and Dilaudid 4 mg. Drs. Onubah, Garfinkel, and Lifson shared an office located at 7035 Reseda Blvd, Suite B in Reseda, CA.<sup>1</sup> The patients were from locations ranging from Los Angeles, Canoga Park, and Panorama City.
- (b) On May 6, 2011, there were 14 prescriptions from the offices of Drs. Onubah, Garfinkel, and Lifson for oxycodone 30 mg, Percocet/Endocet 10/325, and Dilaudid 4 mg. The patients were from locations ranging from Los Angeles, Beverly Hills, and North Hollywood.
- (c) On June 6, 2011, there were 20 prescriptions from the offices of Drs. Onubah, Garfinkel, and Lifson for oxycodone 30 mg and Percocet/Endocet 10/325. The patients were from locations ranging from Los Angeles, Rialto, Hacienda Heights, Gardena, California City, Venice and Moreno Valley.
- (d) On July 21, 2011, there were 17 prescriptions from the offices of Drs. Onubah, Garfinkel, Lifson, and Salari (who also had an office located at 7035 Reseda Blvd, Suite B in Reseda, CA) for oxycodone 30 mg, Percocet/Endocet 10/325, Norco 10/325, Lortab 10/500, and Dilaudid 4 mg. The patients were from locations ranging from Los Angeles, North Hollywood, Sylmar, South Pasadena, Mission Viejo, Palm Springs, and Norwalk.
- (e) On August 16, 2011, there were 16 prescriptions from the offices of Drs.

  Onubah, Garfinkel, Lifson, and Salari for oxycodone 30 mg, Percocet/Endocet 10/325, and

  Dilaudid 4 mg. The patients were from locations ranging from Los Angeles Inglewood, Santa

<sup>&</sup>lt;sup>1</sup> Drs. Garfinkel and Lifson also maintained separate offices.

Monica, Pomona, Compton, Manhattan Beach, Paramount, and Glendale. Respondent Abergel subsequently admitted to a Board Inspector that he was an "idiot" for filling prescriptions from Drs. Onubah, Garfinkel, Lifson, and Salari.

- (f) On January 30, 2012, there were 6 prescriptions from Dr. Arnold in Inglewood for oxycodone 30 mg. The patients were from locations ranging from Compton, Long Beach, and Los Angeles. Also on January 20, 2012, there were 6 prescriptions from Dr. Shamlou in Los Angeles for 30 oxycodone 30 mg. The patients were from locations ranging from Northridge, Mission Hills, and Sylmar. Both doctors gave the same dosage of oxycodone 30 mg for each of their patients.
- (g) On February 2, 2012, there were 11 prescriptions from Dr. Arnold for oxycodone 30 mg. All of the patients had the same dosage.
- (h) On February 9, 2012, there were 10 prescriptions from Dr. Charlap for oxycodone 30 mg. The patients were from locations ranging from Los Angeles, Inglewood, Santa Monica, and Sylmar.

#### SECOND CAUSE FOR DISCIPLINE

## (Failure to Keep Complete Accountability)

36. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under Code section 4301, subdivision (o), in conjunction with Code section 4081, subdivision (a), California Code of Regulations, title 16, section 1718, and Code of Federal Regulations, title 21, section 1304 et seq., on the grounds of unprofessional conduct in that Respondents failed to keep a proper inventory of controlled substances and failed to account for all controlled substances in Respondent Pharmacy. A Board Inspector audited Respondent Pharmacy's records from July 8, 2010 to December 18, 2012 regarding hydromorphone 4 mg, oxycodone 30 mg, and oxycodone/acetaminophen 10/325 (generic and brand for all three drugs). The Board inspector discovered that Respondent Pharmacy had an overage of 74 tablets of hydromorphone 4 mg, an overage of 164 tablets of oxycodone 30 mg, and a shortage of 584 tablets of oxycodone/acetaminophen 10/325.

| //

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

## 

#### 

## 

# 

## 

## 

#### THIRD CAUSE FOR DISCIPLINE

#### (Failure to Notify the Board of Loss of Controlled Substances)

37. Respondent Pharmacy and Respondent Abergel are subject to disciplinary action under Code section 4301, subdivision (o), in conjunction with California Code of Regulations, title 16, section 1715.6, on the grounds of unprofessional conduct in that Respondents failed to report the loss of 400 hydrocodone/apap tablets 5/500 strength, 200 hydrocodone/apap tablets 7.5/750 strength, 480 hydrocodone/apap tablets 10/650 strength, and 440 hydrocodone/apap tablets 10/325 strength. The loss occurred on or about September 3, 2012. Respondents reported the loss to the DEA but failed to report the loss to the Board within 30 days of its occurrence.

#### **OTHER MATTERS**

- 38. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 50146 issued to The Druggist Inc., The Druggist Inc. shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if it is revoked.
- 35. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 50146 issued to The Druggist Inc. while Joel Abergel has been an officer and owner and had knowledge of or knowingly participated in any conduct for which the licensee was disciplined, Joel Abergel shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if it is revoked.

#### DISCIPLINE CONSIDERATIONS

39. To determine the degree of discipline, if any, to be imposed on Respondent Abergel, Complainant alleges that on or about October 31, 2007, the Board of Pharmacy issued a Citation to Respondent Abergel in Case No. CI 2007 34523 in the amount of \$4,000.00 for violating California Code of Regulations, title 16, section 1714, subdivision (d) [theft policy]. That Citation is now final and is incorporated by reference as if fully set forth.

#### **PRAYER**

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- 1. Revoking or suspending Pharmacy Permit Number PHY 50146 issued to The Druggist, Inc.;
- 2. Revoking or suspending Pharmacist License Number RPH 41192 issued to Joel Abergel aka Joelle Abergel;
- 3. Prohibiting The Druggist Inc. from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if Pharmacy Permit Number 50146 issued to The Druggist Inc. is revoked;
- 4. Prohibiting Joel Abergel from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 50146 is placed on probation or until Pharmacy Permit Number PHY 50146 is reinstated if Pharmacy Permit Number 50146 issued to The Druggist Inc. is revoked;
- 5. Ordering The Druggist, Inc. and Joel Abergel aka Joelle Abergel to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; and
  - 6. Taking such other and further action as deemed necessary and proper.

5/3/16

VIRGINIA HEROLD

Board of Pharmacy

Department of Consumer Affairs

State of California Complainant

LA2014512855 51876443\_2.doc